Compare Mesoblast Limited (MESO) vs YieldMax Magnificent 7 Fund of Option Income ETFs (YMAG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Mesoblast Limited vs YieldMax Magnificent 7 Fund of Option Income ETFs — how do they compare? Mesoblast Limited trades at $13.8 (market cap $1.75B), while YieldMax Magnificent 7 Fund of Option Income ETFs trades at $11.48 (market cap $296.92M). The key difference: Mesoblast Limited is far larger — about 5.9× YieldMax Magnificent 7 Fund of Option Income ETFs's market cap, and Mesoblast Limited is more actively traded (239,027 versus 1,023,545). Which is the better fit depends on your goals — on Pluang, investors hold Mesoblast Limited for 14 Days and YieldMax Magnificent 7 Fund of Option Income ETFs for 62 Days on average.
| MESO | YMAG | |
|---|---|---|
Market Cap | $1.75B | $296.92M |
Volume | 239,027 | 1,023,545 |
Sector | Health | Income / Options Overlay |
52-Week High | $20.96 | $15.68 |
52-Week Low | $13.19 | $10.76 |
Typical Hold Time | 14 Days | 62 Days |
Enterprise Value | $1.83B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MESO trades at $13.94, up 2.42% with bearish technical signals from moving averages. The company reported substantial revenue growth to $120 million in 2026 but remains unprofitable with a -47.82% net margin. Recent FDA approval for Ryoncil potency assay and completion of Phase 3 back pain trial represent significant operational milestones. Cash position remains strong at $161.16 million, though debt levels require monitoring.
While MESO shows promising revenue growth and pipeline progress, persistent losses and negative ROE present fundamental challenges. Analyst consensus leans bullish with 45% buy ratings, but technical indicators suggest near-term caution. The stock offers speculative growth potential contingent on successful commercialization and path to profitability.
YMAG trades at $11.49, down 0.69% with a bullish technical signal supported by moving averages. The ETF maintains consistent weekly dividend distributions, though key valuation ratios remain unavailable. Recent news highlights ongoing distribution announcements and trading activity, with the stock showing moderate volatility within a tight $11-12 range.
The outlook remains cautiously optimistic given the bullish technical setup and income generation through dividends. However, risks include NAV stability concerns during earnings periods and dependency on underlying option strategies. Investors should weigh the high distribution yield against potential capital volatility in market downturns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →About YieldMax Magnificent 7 Fund of Option Income ETFs
YMAG is an actively managed 'fund of funds' that provides equal-weighted exposure to the seven YieldMax ETFs tracking the 'Magnificent 7' tech giants (Apple, Microsoft, Alphabet, Amazon, Nvidia, Meta, and Tesla). It seeks to generate high current income by harvesting option premiums across these leaders, offering a streamlined way to access concentrated tech volatility in an income-producing format.
Read more on YMAG →
